Bempegaldesleukin Uses, Dosage, Side Effects and more

Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).

Trade Name Bempegaldesleukin
Generic Bempegaldesleukin
Bempegaldesleukin Other Names Bempegaldesleukin
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share